Publikationen der ALS-Forschungsgruppe an der Charité
Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme
Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J,
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spastic using tetrahydrocannabinol:cannabidiol (THC:CBD)
Meyer T, Funke A, Münch C, Kettemann D, Maier A, Walter B,
Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study
Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, Münch C,
Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach
Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S,
Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation
Kettemann D, Funke A, Maier A, Rosseau S, Meyer R, Spittel S,
Interleukin-1 Antagonist Anakinra in Amyotriphic Lateral Sclerosis – A Pilot Study
Maier A, Deigendesch N, Müller K, Weishaupt JH, Krannich A, Röhle R,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis
Eschbach J, Schwalenstöcker B, Soyal SM,
Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis
Roth NM, Saidha S, Zimmermann H,
The dynactin p150 subunit: cell biology studies of sequence changes found in ALS/MND and Parkinsonian syndromes
Stockmann M, Meyer-Ohlendorf M, Achberger K,
NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis
Blauw HM, van Rheenen W, Koppers
Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients
Lee T, Li YR, Ingre C,
A large genome scan for rare CNVs in amyotrophic lateral sclerosis
Blauw HM, Al-Chalabi A, Andersen PM,
Novel missense and truncating mutations in FUS/TLS in familial ALS
Waibel S, Neumann M, Rabe M,
No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort
Fernández-Santiago R, Sharma M, Berg D,
